Publications - HIV Prevention
-
Hepatotoxicity Among People Living with HIV and Receiving Isoniazid Preventive Therapy in Pregnancy and Postpartum: The Role of Antiretroviral Regimen and Pharmacogenetics
Citation: Grace Montepiedra, Lisa Aaron, Gerhard Theron, Katie McCarthy, Sarah Bradford, Tsungai Chipato, Tichaona Vhembo, Lynda Stranix-Chibanda, Deo Wabwire, Gaerolwe Masheto, Patrick Jean-Philippe, Timothy R Sterling, Adriana Weinberg, Amita Gupta, for the IMPAACT P1078 TB APPRISE Study Team, Hepatotoxicity Among People Living with HIV and Receiving Isoniazid Preventive Therapy in Pregnancy and Postpartum: The Role of Antiretroviral Regimen and Pharmacogenetics, Clinical Infectious Diseases, 2025;, ciaf198, https://doi.org/10.1093/cid/ciaf198
Published: 05/14/2025
-
Regional Differences in Risk of Recurrent Falls Among Older U.S. Women and Men with HIV in the HIV Infection, Aging, and Immune Function Long-Term Observational Study
Citation: Mona Abdo, Xingye Wu, Anjali Sharma, Katherine K. Tassiopoulos, Todd T. Brown, Susan L. Koletar, Michael T. Yin, Kristine M. Erlandson, and the ACTG A5322 Study Team.AIDS Research and Human Retroviruses.ahead of printhttp://doi.org/10.1089/aid.2021.0162
Published: 05/03/2022
-
A randomized clinical trial of HPV test-and-treat as compared to cytology-based screening for prevention of cervical cancer among women living with HIV: AIDS Clinical Trials Group Protocol A5282
Citation: Timothy Wilkin, Huichao Chen, Vikrant Sahasrabuddhe, Roy Matining, Rosie Mngqibisa, Lameck Chinula, Yamikani Mbilizi, Tsitsi Magure, Ayotunde E Omoz-Oarhe, Mohammed Rassool, Cynthia Riviere, Rhamesh Bhosale, Sheela Godbole, Reena Naranjo, Robert Coombs, Pamela Michelow, Catherine Godfrey, Cynthia Firnhaber, A randomized clinical trial of HPV test-and-treat as compared to cytology-based screening for prevention of cervical cancer among women living with HIV: AIDS Clinical Trials Group Protocol A5282, Clinical Infectious Diseases, 2022;, ciac213, https://doi.org/10.1093/cid/ciac213
Published: 05/03/2022
-
The impact of short term Antiretroviral Therapy (ART) interruptions on longer term maternal health outcomes-A randomized clinical trial
Citation: Atuhaire P, S Brummel S, Mmbaga BT, Angelidou K, Fairlie L, Violari A, Theron G, Mukuzunga C, Mawlana S, Mubiana-Mbewe M, Naidoo M, Makanani B, Mandima P, Nematadzira T, Suryavanshi N, Mbengeranwa T, Loftis A, Basar M, McCarthy K, Currier JS, Fowler MG; 1077BF/1077FF PROMISE Team. The impact of short term Antiretroviral Therapy (ART) interruptions on longer term maternal health outcomes-A randomized clinical trial. PLoS One. 2020 Jan 30;15(1):e0228003. doi: 10.1371/journal.pone.0228003. PMID: 31999753; PMCID: PMC6992010.
Published: 07/13/2021
-
Pharmacogenetic interactions of rifapentine plus isoniazid with efavirenz or nevirapine
Citation: Haas DW, Podany AT, Bao Y, Swindells S, Chaisson RE, Mwelase N, Supparatpinyo K, Mohapi L, Gupta A, Benson CA, Baker P, Fletcher CV. Pharmacogenetic interactions of rifapentine plus isoniazid with efavirenz or nevirapine. Pharmacogenet Genomics. 2021 Jan;31(1):17-27. doi: 10.1097/FPC.0000000000000417. PMID: 32815870; PMCID: PMC7655626.
Published: 01/15/2021
-
Nevirapine pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for TB prevention
Citation: Podany AT, Leon-Cruz J, Hakim J, Supparatpinyo K, Omoz-Oarhe A, Langat D, Mwelase N, Kanyama C, Gupta A, Benson CA, Chaisson RE, Swindells S, Fletcher CV; AIDS Clinical Trials Group A5279 Team. Nevirapine pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for TB prevention. J Antimicrob Chemother. 2020 Nov 26:dkaa470. doi: 10.1093/jac/dkaa470. Epub ahead of print. PMID: 33241266.
Published: 11/26/2020
-
Pharmacokinetics and drug-drug interactions of isoniazid and efavirenz in pregnant women living with HIV in high TB incidence settings: importance of genotyping
Citation: Gausi K, Wiesner L, Norman J, Wallis CL, Onyango-Makumbi C, Chipato T, Haas DW, Browning R, Chakhtoura N, Montepiedra G, Aaron L, McCarthy K, Bradford S, Vhembo T, Stranix-Chibanda L, Masheto GR, Violari A, Mmbaga BT, Aurpibul L, Bhosale R, Nevrekhar N, Rouzier V, Kabugho E, Mutambanengwe M, Chanaiwa V, Nyati M, Mhembere T, Tongprasert F, Hesseling A, Shin K, Zimmer B, Costello D, Jean-Philippe P, Sterling TR, Theron G, Weinberg A, Gupta A, Denti P; IMPAACT P1078 (TB APPRISE) Study Group Team. Pharmacokinetics and drug-drug interactions of isoniazid and efavirenz in pregnant women living with HIV in high TB incidence settings: importance of genotyping. Clin Pharmacol Ther. 2020 Sep 9. doi: 10.1002/cpt.2044. Epub ahead of print. PMID: 32909316.
Published: 09/09/2020
-
The effect of TB treatment on health-related quality of life for people with advanced HIV
Citation: Opollo V, Sun X, Lando R, Miyahara S, Torres TS, Hosseinipour MC, Bisson GP, Kumwenda J, Gupta A, Nyirenda M, Katende K, Suryavanshi N, Beulah F, Shah NS. The effect of TB treatment on health-related quality of life for people with advanced HIV. Int J Tuberc Lung Dis. 2020 Sep 1;24(9):910-915. doi: 10.5588/ijtld.19.0716. PMID: 33156757.
Published: 09/01/2020
-
An Evaluation of Baseline Kidney Function in the REPRIEVE Trial of Pitavastatin in Human Immunodeficiency Virus
Citation: Edgar T Overton, Amy Kantor, Kathleen V Fitch, Paul Muntner, Khuanchai Supparatpinyo, Mosepele Mosepele, Lerato Mohapi, Sandra Wagner Cardoso, Sandesh Patil, Marcus V G de Lacerda, Grace McComsey, Judith A Aberg, Pamela S Douglas, Steven K Grinspoon, Heather Ribaudo, Christina M Wyatt, An Evaluation of Baseline Kidney Function in the REPRIEVE Trial of Pitavastatin in Human Immunodeficiency Virus, The Journal of Infectious Diseases, Volume 222, Issue Supplement_1, 1 August 2020, Pages S41–S51, https://doi.org/10.1093/infdis/jiaa222
Published: 08/01/2020
-
Physical Function Impairment and Frailty in Middle-Aged People Living With Human Immunodeficiency Virus in the REPRIEVE Trial Ancillary Study PREPARE
Citation: Triin Umbleja, Todd T Brown, Edgar T Overton, Heather J Ribaudo, Jennifer A Schrack, Kathleen V Fitch, Pamela S Douglas, Steven K Grinspoon, Sarah Henn, Roberto C Arduino, Benigno Rodriguez, Constance A Benson, Kristine M Erlandson, for the ACTG A5361S (PREPARE) Team, Physical Function Impairment and Frailty in Middle-Aged People Living With Human Immunodeficiency Virus in the REPRIEVE Trial Ancillary Study PREPARE, The Journal of Infectious Diseases, Volume 222, Issue Supplement_1, 1 August 2020, Pages S52–S62, https://doi.org/10.1093/infdis/jiaa249
Published: 08/01/2020
-
Effects of Pregnancy and Isoniazid Preventive Therapy on M. tuberculosis Interferon Gamma Response Assays in Women with HIV
Citation: Weinberg A, Aaron L, Montepiedra G, Sterling TR, Browning R, Mmbaga B, Vhembo T, Naik S, Kabugho E, Masheto G, Pahwa S, Mathad JS, LaCourse SM, McCarthy K, Bradford S, Theron G, Costello D, Zimmer B, Pierre MF, Gausi K, Denti P, Haas DW, Gupta A; IMPAACT P1078 study team. Effects of Pregnancy and Isoniazid Preventive Therapy on M. tuberculosis Interferon Gamma Response Assays in Women with HIV. Clin Infect Dis. 2020 Jul 28:ciaa1083. doi: 10.1093/cid/ciaa1083. Epub ahead of print. PMID: 32720695.
Published: 07/28/2020
-
TB prevention strategies and unanswered questions for pregnant and postpartum women living with HIV: the need for improved evidence
Citation: Mathad JS, LaCourse SM, Gupta A. TB prevention strategies and unanswered questions for pregnant and postpartum women living with HIV: the need for improved evidence. J Int AIDS Soc. 2020 Mar;23(3):e25481. doi: 10.1002/jia2.25481. PMID: 32202066.
Published: 03/23/2020
-
High prevalence of late presentation of ART-naïve perinatally infected children for care in Pune, India
Citation: Nimkar S, Kinikar A, Chavan A, Sangle S, Rewari B, Gupta G, Mave V, Marbaniang I. High prevalence of late presentation of ART-naïve perinatally infected children for care in Pune, India. AIDS Care. 2020 Feb 19:1-6. PMID: 32070118.
Published: 02/18/2020
-
A parsimonious host inflammatory biomarker signature predicts incident TB and mortality in advanced HIV
Citation: Yukari C Manabe, MD; Bruno B Andrade; Nikhil Gupte; Samantha Leong; Manisha Kintali; Mitch Matoga; Cynthia Riviere; Wadzanai Sameneka; Javier R Lama; Kogieleum Naidoo; Yue Zhao; William Evan Johnson; Jerrold Ellner, MD; Mina C Hosseinipour; Gregory P Bisson; Padmini Salgame, PhD; Amita Gupta, MD. A parsimonious host inflammatory biomarker signature predicts incident TB and mortality in advanced HIV. Clin Infect Dis. 2019 Nov 25. pii: ciz1147. doi: 10.1093/cid/ciz1147. [Epub ahead of print]. PMID: 31761933.
Published: 11/25/2019
-
Incidence of tuberculosis in HIV-infected adults on first- and second-line antiretroviral therapy in India.
Citation: Gupte AN, Kadam D, Sangle S, Rewari BB, Salvi S, Chavan A, Nimkar S, Golub J, Gupte N, Gupta A, Marbaniang I, Mave V. Incidence of tuberculosis in HIV-infected adults on first- and second-line antiretroviral therapy in India. BMC Infect Dis. 2019 Oct 29;19(1):914. doi: 10.1186/s12879-019-4569-z. PMID: 31664933; PMCID: PMC6820927.
Published: 10/29/2019
-
Isoniazid preventive therapy in HIV-infected pregnant and postpartum women
Citation: Gupta A, Montepiedra G, Aaron L, Theron G, McCarthy K, Bradford S, Chipato T, Vhembo T, Stranix-Chibanda L, Onyango-Makumbi C, Masheto GR, Violari A, Mmbaga BT, Aurpibul L, Bhosale R, Mave V, Rouzier V, Hesseling A, Shin K, Zimmer B, Costello D, Sterling TR, Chakhtoura N, Jean-Philippe P, Weinberg A. Isoniazid preventive therapy in HIV-infected pregnant and postpartum women. N Engl J Med. 2019 Oct 3;381(14):1333-1346. PMID: 31577875.
Published: 10/03/2019
-
Depression, sexual behavior, and HIV treatment outcomes among transgender women, cisgender women and men who have sex with men living with HIV in Brazil and Thailand: a short report
Citation: Poteat T, Celentano DD, Mayer KH, Beyrer C, Mimiaga M, Friedman R, Srithanaviboonchai K, Safren S, for the HPTN 063 Study Team. Depression, sexual behavior, and HIV treatment outcomes among transgender women, cisgender women and men who have sex with men living with HIV in Brazil and Thailand: a short report. AIDS Care. 2019 Sep 17:1-6. doi: 10.1080/09540121.2019.1668526. PMID: 31530004
Published: 09/17/2019
-
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. Reply
Citation: Chaisson RE, Ramchandani R, Swindells S. One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. Reply. N Engl J Med. 2019 Sep 12;381(11):e23. doi: 10.1056/NEJMc1908492. PMID: 31509690. (Letter)
Published: 09/12/2019
-
Gait speed decline is associated with hemoglobin A1C, neurocognitive impairment, and black race in persons with HIV
Citation: Masters MC, Perez J, Tassiopoulos K, Andrade A, Ellis R, Yang J, Brown T, Palella FJ, Erlandson KM. Gait speed decline is associated with hemoglobin A1C, neurocognitive impairment, and black race in persons with HIV. AIDS Res Hum Retroviruses. 2019 Aug 30. doi: 10.1089/AID.2019.0101. [Epub ahead of print] PMID: 31468979
Published: 08/30/2019
-
Inclusion of key populations in clinical trials of new antituberculosis treatments: Current barriers and recommendations for pregnant and lactating women, children, and HIV-infected persons
Citation: Gupta A, Hughes MD, Garcia-Prats AJ, McIntire K, Hesseling AC. Inclusion of key populations in clinical trials of new antituberculosis treatments: Current barriers and recommendations for pregnant and lactating women, children, and HIV-infected persons. PLoS Med. 2019 Aug 15;16(8): e1002882. https://doi.org/10.1371/journal.pmed.1002882. PMID: 31415563 PMCID: PMC6695091.
Published: 08/15/2019
-
Risk factors for adverse birth outcomes in the PROMISE 1077BF/1077FF Trial
Citation: Sebikari D, Farhad M, Fenton T, Owor M, Stringer JSA, Qin M, Chakhtoura N, Chi BH, Saidi F, Nevrekar N, Violari A, Chipato T, McIntyre JA, Moodley D, Taha TE, Theron G, Fowler MG. Risk factors for adverse birth outcomes in the PROMISE 1077BF/1077FF Trial. J Acquir Immune Defic Syndr. 2019 Aug 15;81(5):521-532. doi: 10.1097/QAI.0000000000002072. PMID: 31295174; PubMed PMCID: PMC6702964.
Published: 08/15/2019
-
Does Venue Type Matter for HIV-Related Risk Behavior in Urban Adolescent and Young Adult Men Who Have Sex With Men?
Citation: Arrington-Sanders R, Fields E, Greenberg L, Henry-Reid L, Stines S, Korelitz J, Kapogiannis B, Ellen J, Boyer CB, and the Adolescent Medicine Trials Network for HIV/AIDS Interventions. Does venue type matter for HIV-related risk behavior in urban adolescent and young adult men who have sex with men? Youth Soc. 2019 Aug;51(8). https://doi.org/10.1177/0044118X17723655
Published: 08/08/2019
-
Long-term outcomes in a large randomized trial of HIV-1 salvage therapy: 96-week results of AIDS Clinical Trials Group A5241 (OPTIONS)
Citation: Gandhi RT, Tashima KT, Smeaton LM, Vu V, Ritz J, Andrade A, Eron JJ, Hogg E, Fichtenbaum CJ; ACTG A5241 Study Team. Long-term outcomes in a large randomized trial of HIV-1 salvage therapy: 96-week results of AIDS Clinical Trials Group A5241 (OPTIONS). J Infect Dis. 2019 May 28. pii: jiz281. doi: 10.1093/infdis/jiz281. [Epub ahead of print] PMID: 31135883
Published: 05/28/2019
-
High prevalence of insulin resistance and occurrence prior to hyperinsulinemia threshold among people living with HIV in Pune, India
Citation: Marbaniang I, Sangle S, Salvi S, Kulkarni K, Shere D, Deshpande P, Nimkar S, Gupta A, Mave V. High prevalence of insulin resistance and occurrence prior to hyperinsulinemia threshold among people living HIV in Pune, India. Diabetes Metabolic Syndrome: Clinical Research & Reviews. May-June 2019;13(3):1813-1819.
Published: 05/21/2019
-
Human Immunodeficiency Virus Type 1 and Tuberculosis Coinfection in Multinational, Resource-limited Settings: Increased Neurological Dysfunction
Citation: Robertson KR, Oladeji B, Jiang H, Kumwenda J, Supparatpinyo K, Campbell TB, Hakim J, Tripathy S, Hosseinipour MC, Marra CM, Kumarasamy N, Evans S, Vecchio A, La Rosa A, Santos B, Silva MT, Montano S, Kanyama C, Firnhaber C, Price R, Marcus C, Berzins B, Masih R, Lalloo U, Sanne I, Yosief S, Walawander A, Nair A, Sacktor N, Hall C; 5199 Study Team; and the AIDS Clinical Trials Group. Human Immunodeficiency Virus Type 1 and Tuberculosis Coinfection in Multinational, Resource-limited Settings: Increased Neurological Dysfunction. Clin Infect Dis. 2019 May 2;68(10):1739-1746. doi: 10.1093/cid/ciy718. PMID: 30137250; PMCID: PMC6495021
Published: 05/02/2019
-
Quantitative Human Immunodeficiency Virus (HIV)-1 antibodies correlate with plasma HIV-1 RNA and cell-associated DNA levels in children on antiretroviral therapy
Citation: McManus M, Henderson J, Gautam A, Brody R, Weiss ER, Persaud D, Mick E, Luzuriaga K; PACTG 356 Investigators. Quantitative Human Immunodeficiency Virus (HIV)-1 antibodies correlate with plasma HIV-1 RNA and cell-associated DNA levels in children on antiretroviral therapy. Clin Infect Dis. 2019 May 2;68(10):1725-1732. PMID: 30668843; PMCID: PMC6495016
Published: 05/02/2019
-
Model-Based Methods to Translate Adolescent Medicine Trials Network for HIV/AIDS Interventions Findings Into Policy Recommendations: Rationale and Protocol for a Modeling Core (ATN 161)
Citation: Neilan AM, Patel K, Agwu AL, Bassett IV, Amico KR, Crespi CM, Gaur AH, Horvath KJ, Powers KA, Rendina HJ, Hightow-Weidman LB, Li X, Naar S, Nachman S, Parsons JT, Simpson KN, Stanton BF, Freedberg KA, Bangs AC, Hudgens MG, Ciaranello AL. Model-Based Methods to Translate Adolescent Medicine Trials Network for HIV/AIDS Interventions Findings Into Policy Recommendations: Rationale and Protocol for a Modeling Core (ATN 161). JMIR Res Protoc. 2019 Apr 16;8(4):e9898. doi: 10.2196/resprot.9898. PMID: 30990464; PMCID: PMC6488956
Published: 04/16/2019
-
Feasibility of identifying household contacts of rifampin- and multidrug-resistant tuberculosis cases at high risk of progression to tuberculosis disease
Citation: Gupta A, Swindells S, Kim S, Hughes MD, Naini L, Wu X, Dawson R, Mave V, Sanchez J, Mendoza A, Gonzales P, Kumarasamy N, Comins K, Conradie F, Shenje J, Fontain SN, Garcia-Prats A, Asmelash A, Nedsuwan S, Mohapi L, Lalloo UG, Ferreira ACG, Mugah C, Harrington M, Jones L, Cox S, Smith B, Shah NS, Hesseling AC, Churchyard G, ACTG 5300/IMPAACT I2003 PHOENIx Feasibility study team. Feasibility of identifying household contacts of rifampin- and multidrug-resistant tuberculosis cases at high risk of progression to tuberculosis disease. Clin Infect Dis. 2019 Mar 28. pii: ciz235. doi: 10.1093/cid/ciz235. [Epub ahead of print] PMID: 30942853
Published: 03/28/2019
-
One month of rifapentine plus isoniazid to prevent HIV-related tuberculosis
Citation: Swindells S, Ramchandani R, Gupta A, Benson CA, Leon-Cruz J, Mwelase N, Jean Juste MA, Lama JR, Valencia J, Omoz-Oarhe A, Supparatpinyo K, Masheto G, Mohapi L, da Silva Escada RO, Mawlana S, Banda P, Severe P, Hakim J, Kanyama C, Langat D, Moran L, Andersen J, Fletcher CV, Nuermberger E, Chaisson RE; BRIEF TB/A5279 Study Team. One month of rifapentine plus isoniazid to prevent HIV-related tuberculosis. N Engl J Med. 2019 Mar 14;380(11):1001-1011. doi: 10.1056/NEJMoa1806808. PMID: 30865794; PMCID: PMC6563914.
Published: 03/14/2019
-
Elevated highly sensitive C-reactive protein and d-dimer levels are associated with food insecurity among people living with HIV in Pune, India.
Citation: Patil S, Kadam D, Mehtani N, Sangle S, Marbaniang I, Kulkarni V, Shere D, Dhumal G, Suryavanshi N, Gupte N, Bollinger R, DeLuca A, Nevarekar N, Menon P, Kawade R, Patil M; Gupta A, Mave V. Elevated Highly Sensitive C-Reactive Protein and D-dimer Levels are Associated with Food Insecurity among People Living with HIV in Pune, India. Public Health Nutr. 2019 Mar 4:1-8. doi: 10.1017/S136898001900020X. [Epub ahead of print] PMID: 30827288.
Published: 03/04/2019
-
Cerebrospinal fluid viral escape in aviremic HIV-infected patients receiving antiretroviral therapy: prevalence, risk factors and neurocognitive effects
Citation: Pérez-Valero I, Ellis R, Heaton R, Deutsch R, Franklin D, Clifford DB, Collier A, Gelman B, Marra C, McCutchan JA, Navis A, Sacktor N, Simpson D, Grant I, Letendre S. Cerebrospinal fluid viral escape in aviremic HIV-infected patients receiving antiretroviral therapy: prevalence, risk factors and neurocognitive effects. AIDS. 2019 Mar 1;33(3):475-481. doi: 10.1097/QAD.0000000000002074. PMID: 30702516; PMCID: PMC6361539
Published: 03/01/2019
-
Improvements in HIV care continuum needed to meaningfully reduce HIV incidence among men who have sex with men in Baltimore, US: a modelling study for HPTN 078
Citation: Mitchell KM, Hoots B, Dimitrov D, German D, Flynn C, Farley JE, Gelman M, Hughes J, Donnell D, Adeyeye A, Remien R, Beyrer C, Paz-Bailey G, Boily M. Improvements in HIV care continuum needed to meaningfully reduce HIV incidence among men who have sex with men in Baltimore, US: a modelling study for HPTN 078. J Int AIDS Soc. 2019 Mar;22(3):e25246. doi: 10.1002/jia2.25246. PMID: 30868739. PMCID: PMC6416473
Published: 03/01/2019
-
Sexual partner characteristics, relationship type, and HIV risk among a community venue-based sample of urban adolescent and young adult men who have sex with men
Citation: Boyer C, Greenberg L, Korelitz J, Harper G, Stewart-Campbell R, Straub D, Sanders R, Henry-Reid L, Futterman D, Lee S , Ellen J, and the Adolescent Medicine Trials Network for HIV/AIDS Interventions. Sexual partner characteristics, relationship type, and HIV risk among a community venue-based sample of urban adolescent and young adult men who have sex with men. Youth Soc. 2019 Mar;51(2):219-246. PMID: 30983642; PMCID: PMC6456077
Published: 03/01/2019
-
The pharmacokinetics, pharmacodynamics, and mucosal responses to maraviroc-containing PrEP regimens in MSM
Citation: McGowan I, Wilkin T, Landovitz RJ, Wu C, Chen Y, Marzinke MA, Hendrix CW, Richardson P, Eshleman SH, Andrade A, Chege W, Anderson PL, Mccauley M, Farley J, Mayer KH, Anton P, Brand RM, Cranston RD, Gulick R. The pharmacokinetics, pharmacodynamics, and mucosal responses to maraviroc-containing PrEP regimens in MSM. AIDS 2018 Dec 13. doi: 10.1097/QAD.0000000000002038. PMCID pending
Published: 02/01/2019
-
Interest of Youth Living With HIV in Long-Acting Antiretrovirals
Citation: Weld ED, Rana MS, Dallas RH, Camacho-Gonzalez AF, Ryscavage P, Gaur AH, Chakraborty R, Swindells S, Flexner C, Agwu AL. Interest of Youth Living With HIV in Long-Acting Antiretrovirals. J Acquir Immune Defic Syndr. 2019 Feb 1;80(2):190-197. doi: 10.1097/QAI.0000000000001896. PMID: 30418298; PMCID: PMC6331217
Published: 02/01/2019
-
Genetic complexity in the replication-competent latent HIV reservoir increases with untreated infection duration in infected youth
Citation: Brumme ZL, Sudderuddin H, Ziemniak C, Luzuriaga K, Jones BR, Joy JB, Cunningham CK, Greenough T, Persaud D. Genetic complexity in the replication-competent latent HIV reservoir increases with untreated infection duration in infected youth. AIDS. 2019 Feb 1;33(2):211-218. PMID: 30325763; PMCID: PMC6298800
Published: 02/01/2019
-
Is there a connection between gestational diabetes, human immunodeficiency virus infection, and tuberculosis?
Citation: Alexander M, Gupta A, Mathad JS. Is there a connection between gestational diabetes, HIV, and tuberculosis? Int J Tuberc Lung Dis. 2019 Jan1;23(1):19-25(7). doi: https://doi.org/10.5588/ijtld.18.0337. PMID: 30674375.
Published: 01/01/2019
-
The Latent Human Immunodeficiency Virus (HIV) Reservoir Resides Primarily in CD32-CD4+ T Cells in Perinatally HIV-Infected Adolescents With Long-Term Virologic Suppression
Citation: Dhummakupt A, Siems LV, Singh D, Chen YH, Anderson T, Collinson-Streng A, Zhang H, Patel P, Agwu A, Persaud D. The Latent Human Immunodeficiency Virus (HIV) Reservoir Resides Primarily in CD32-CD4+ T Cells in Perinatally HIV-Infected Adolescents With Long-Term Virologic Suppression. J Infect Dis. 2019 Jan 1;219(1):80-88. doi: 10.1093/infdis/jiy461. PMID: 30053296; PMCID: PMC6284548
Published: 01/01/2019
-
No change in health-related quality of life for at-risk U.S. women and men starting HIV pre-exposure prophylaxis (PrEP): Findings from HPTN 069/ACTG A5305
Citation: Kapadia SN, Wu C, Mayer KH, Wilkin TJ, Amico KR, Landovitz RJ, Andrade A, Chen YQ, Chege W, McCauley M, Gulick RM, Schackman BR. No change in health-related quality of life for at-risk U.S. women and men starting HIV pre-exposure prophylaxis (PrEP): Findings from HPTN 069/ACTG A5305. PLoS One. 2018 Dec 26;13(12):e0206577. doi: 10.1371/journal.pone.0206577. eCollection 2018. PMID: 30586364; PMCID: PMC6306196
Published: 12/26/2018
-
Maternal health outcomes among HIV-infected breastfeeding women with high CD4 counts: results of a treatment strategy trial
Citation: Hoffman RM, Angelidou KN, Brummel SS, Saidi F, Violari A, Dula D, Mave V, Fairlie L, Theron G, Kamateeka M, Chipato T, Chi BH, Stranix-Chibanda L, Nematadzira T, Moodley D, Bhattacharya D, Gupta A, Coletti A, McIntyre JA, Klingman KL, Chakhtoura N, Shapiro DE, Fowler MG, Currier JS for the IMPAACT PROMISE 1077BF/FF team. Maternal health outcomes among HIV-infected breastfeeding women with high CD4 counts: results of a treatment strategy trial. HIV Clin Trials. 2018 Dec;19(6):209-224. doi: 10.1080/15284336.2018.1537327.
Published: 12/15/2018
-
Impact of providing pre-exposure prophylaxis for HIV at clinics for sexually transmitted infections in Baltimore City: an agent-based model
Citation: Kasaie P, Berry SA, Shah MS, Rosenberg ES, Hoover KW, Gift TL, Chesson H, Pennington J, German D, Flynn CP, Beyrer C, Dowdy DW. Impact of providing pre-exposure prophylaxis for HIV at clinics for sexually transmitted infections in Baltimore City: an agent-based model. Sex Transm Dis. 2018 Dec;45(12):791-797. doi: 10.1097/OLQ.0000000000000882. PMID: 29944642; PMCID: PMC6339460
Published: 12/01/2018
-
Effect of antiretroviral therapy on plasma concentrations of chloroquine and desethyl-chloroquine
Citation: Ippolito MM, Jacobson JM, Lederman MM, Winterberg M, Tarning J, Shapiro TA, Flexner C. Effect of antiretroviral therapy on plasma concentrations of chloroquine and desethyl-chloroquine. Clin Infect Dis. 2018 Oct 30;67(10):1617-1620. doi: 10.1093/cid/ciy405. PMID: 29771277; PMC6206114
Published: 10/30/2018
-
AIDS Clinical Trials Group A5342 Protocol Team. Randomized clinical trial to assess the impact of the broadly neutralizing HIV-1 monoclonal antibody VRC01 on HIV-1 persistence in individuals on effective ART
Citation: Riddler SA, Zheng L, Durand CM, Ritz J, Koup RA, Ledgerwood J, Bailer RT, Koletar SL, Eron JJ, Keefer MC, Macatangay BJC, Cyktor JC, Mellors JW; AIDS Clinical Trials Group A5342 Protocol Team. Randomized clinical trial to assess the impact of the broadly neutralizing HIV-1 monoclonal antibody VRC01 on HIV-1 persistence in individuals on effective ART. Open Forum Infect Dis. 2018 Oct 20;5(10):ofy242. doi: 10.1093/ofid/ofy242. eCollection 2018 Oct. PMID: 30364428 PMCID: PMC6195652
Published: 10/20/2018
-
Intestinal barrier dysfunction and microbial translocation in HIV-infected pregnant women is associated with preterm birth
Citation: Shivakoti R, Gupte N, Kumar NP, Kulkarni V, Balasubramanian U, Bhosale R, Sambrey P, Kinikar A, Bharadwaj R, Patil S, Inamdar S, Suryavanshi N, Babu S, Bollinger RC, Gupta A. Intestinal barrier dysfunction and microbial translocation in HIV-infected pregnant women is associated with preterm birth. Clin Infect Dis. 2018 Sep 14;67(7):1103-1109. doi: 10.1093/cid/ciy253. PMID: 29590318 PMCID. PMC6137119 [Available on 2019-09-14].
Published: 09/14/2018
-
Intestinal integrity biomarkers in early antiretroviral-treated perinatally HIV-1-infected infants
Citation: Koay WLA, Lindsey JC, Uprety P, Bwakura-Dangarembizi M, Weinberg A, Levin MJ, Persaud D. Intestinal integrity biomarkers in early antiretroviral-treated perinatally HIV-1-infected infants. J Infect Dis. 2018 Aug 24;218(7):1085-1089. PMID: 29762690; PMCID: PMC6107740
Published: 08/24/2018
-
As-needed vs immediate etoposide chemotherapy in combination with antiretroviral therapy for mild-to-moderate AIDS-associated kaposi sarcoma in resource-limited settings:
Citation: Hosseinipour MC, Kang M, Krown SE, Bukuru A, Umbleja T, Martin JN, Orem J, Godfrey C, Hoagland B, Mwelase N, Langat D, Nyirenda M, MacRae J, Borok M, Samaneka W, Moses A, Mngqbisa R, Busakhala N, Martínez-Maza O, Ambinder R, Dittmer DP, Nokta M, Campbell TB; A5264/AMC-067 REACT-KS Team. As-needed vs immediate etoposide chemotherapy in combination with antiretroviral therapy for mild-to-moderate AIDS-associated kaposi sarcoma in resource-limited settings: A5264/AMC-067 randomized clinical trial. Clin Infect Dis. 2018 Jul 2;67(2):251-260. doi: 10.1093/cid/ciy044. PMID: 29365083; PMCID: PMC6030807
Published: 07/02/2018
-
Changes in plasma RANKL-osteoprotegerin in a prospective, randomized clinical trial of initial antiviral therapy: A5260s
Citation: Kelesidis T, Moser C, Johnson E, Stein JH, Dubé MP, Yang O, McComsey GA, Currier JS, Brown TT. Changes in plasma RANKL-osteoprotegerin in a prospective, randomized clinical trial of initial antiviral therapy: A5260s. J Acquir Immune Defic Syndr. 2018 Jul 1;78(3):362-366. doi: 10.1097/QAI.0000000000001679. PMID: 29533303. PMCID: PMC5997510.
Published: 07/01/2018
-
Effect of baseline micronutrient and inflammation status on CD4 recovery post-cART initiation in the multinational PEARLS trial
Citation: Shivakoti R, Ewald ER, Gupte N, Yang WT, Kanyama C, Cardoso SW, Santos B, Supparatpinyo K, Badal-Faesen S, Lama JR, Lalloo U, Zulu F, Pawar JS, Riviere C, Kumarasamy N, Hakim J, Pollard R, Detrick B, Balagopal A, Asmuth DM, Semba RD, Campbell TB, Golub J, Gupta A; NWCS 319 and ACTG PEARLS Study Team. Effect of baseline micronutrient and inflammation status on CD4 recovery post-cART initiation in the multinational PEARLS trial. Clin Nutr. 2018 May 29. pii: S0261-5614(18)30199-7. doi: 10.1016/j.clnu.2018.05.014. PMID: 29885777.
Published: 05/29/2018
-
Hepatotoxicity during isoniazid preventive therapy and antiretroviral therapy in people living with HIV with severe immunosuppression: a secondary analysis of a multi-country open-label randomized controlled clinical trial
Citation: Ngongondo M, Miyahara S, Hughes MD, Sun X, Bisson GP, Gupta A, Kumwenda J, Lavenberg JA, Torres TS, Nyirenda M, Kidonge KK, Hosseinipour MC; AIDS Clinical Trials Group A5274 (REMEMBER) Study Team. Hepatotoxicity during isoniazid preventive therapy and antiretroviral therapy in people living with HIV with severe immunosuppression: a secondary analysis of a multi-country open-label randomized controlled clinical trial. J Acquir Immune Defic Syndr. 2018 May 1;78(1):54-61. doi: 10.1097/QAI.0000000000001641. PMID: 29406428; PMCID: PMC5889344.
Published: 05/01/2018
-
Genetic variation of the kinases that phosphorylate tenofovir and emtricitabine in peripheral blood mononuclear cells
Citation: Figueroa DB, Madeen EP, Tillotson J, Richardson P, Cottle L, McCauley M, Landovitz RJ, Andrade A, Hendrix CW, Mayer KH, Wilkin T, Gulick RM, Bumpus NN. Genetic variation of the kinases that phosphorylate tenofovir and emtricitabine in peripheral blood mononuclear cells. AIDS Res Hum Retroviruses. 2018 May;34(5):421-429. doi: 10.1089/AID.2017.0243. Epub 2018 Mar 20. PMID: 29455571; PMCID: PMC5934973
Published: 05/01/2018
-
Live respiratory syncytial virus (RSV) vaccine candidate containing stabilized temperature-sensitivity mutations is highly attenuated in RSV-seronegative infants and children
Citation: Buchholz UJ, Cunningham CK, Muresan P, Gnanashanmugam D, Sato P, Siberry GK, Rexroad V, Valentine M, Perlowski C, Schappell E, Thumar B, Luongo C, Barr E, Aziz M, Yogev R, Spector SA, Collins PL, McFarland EJ, Karron RA; International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1114 Study Team. Live respiratory syncytial virus (RSV) vaccine candidate containing stabilized temperature-sensitivity mutations is highly attenuated in RSV-seronegative infants and children. J Infect Dis. 2018 Apr 11;217(9):1338-1346. doi: 10.1093/infdis/jiy066. PMID: 29509929; PMCID: PMC5894088
Published: 04/11/2018
-
Prevention of HIV-1 transmission through breastfeeding:efficacy of safety of maternal antiretroviral therapy versus infant nevirapine prophylaxis for duration of breastfeeding in HIV-1-infected women with high CD4 cell count (IMPAACT PROMISE)
Citation: Flynn PM, Taha TE, Cababasay M, Fowler MG, Mofenson LM, Owor M, Fiscus S, Stranix-Chibanda L, Coutsoudis A, Ganashanmugam D, Chakhtoura N, McCarthy K, ,Mukuzunga C, Makanani B, Moodley D, Nematadzira T, Kusakara B, Patil S, Vhembo T, Bobat R, Mmbaga BT, Masenya M, Nyati M, Theron G, Mulenga H, Butler K, Shapiro DE, PROMISE Study Team. Prevention of HIV-1 transmission through breastfeeding: efficacy of safety of maternal antiretroviral therapy versus infant nevirapine prophylaxis for duration of breastfeeding in HIV-1-infected women with high CD4 cell count (IMPAACT PROMISE): a randomized, open-label, clinical trial. J Acquir Immune Defic Syndr 2018 Apr 1:77(4):383-392. doi: 10.1097/QAI.0000000000001612. PMID: 29239901, PMCID: PMC5825265.
Published: 04/01/2018
-
Loss to follow‐up and mortality among HIV‐infected adolescents receiving antiretroviral therapy in Pune, India
Citation: Nimkar S, Valvi C, Kadam D, Rewari BB, Kinikar A, Gupte N, Suryavanshi N, Deluca A, Shankar A, Golub J, Bollinger R, Gupta A, Marbaniang I, Mave V. Loss to follow‐up and mortality among HIV‐infected adolescents receiving antiretroviral therapy in Pune, India. HIV Med. 2018 Jul;19(6):395-402. doi: 10.1111/hiv.12605. Epub 2018 Mar 24. PMID: 29573312 PMCID. PMC6082173 [Available on 2019-07-01].
Published: 03/24/2018
-
B and T cell phenotypic profiles of African HIV-infected and HIV-exposed uninfected infants: associations with antibody responses to the pentavalent rotavirus vaccine
Citation: Weinberg A, Lindsey J, Bosch R, Persaud D, Sato P, Ogwu A, Asmelash A, Bwakura-Dangarambezi M, Chi BH, Canniff J, Lockman S, Simani G, Sikhuilile M, Smith CE, Moraka NO and Levin MJ. B and T cell phenotypic profiles of African HIV-infected and HIV-exposed uninfected infants: associations with antibody responses to the pentavalent rotavirus vaccine. Front Immunol. 2018 Jan 19;8:2002. PMID: 29403482; PMCID: PMC5780413
Published: 01/19/2018
-
Gender-based violence screening methods preferred by women visiting a public hospital in Pune, India
Citation: Suryavanshi N, Naik S, Waghmare S, Gupte N, Khan S, Mave V, Deluca A, Gupta A, Golub J, Bollinger RC, Shankar A. Gender-based violence screening methods preferred by women visiting a public hospital in Pune, India. BMC Womens Health. 2018 Jan 15;18(1):19. doi: 10.1186/s12905-018-0515-2. PMID: 29334936. PMCID: PMC5769341.
Published: 01/15/2018
-
Vitamin D3 supplementation increases spine bone mineral density in adolescents and young adults with human immunodeficiency deficiency virus infection being treated with tenofovir disoproxil fumarate: A randomized, placebo-controlled trial
Citation: Havens PL, Stephensen CB, Van Loan MD, Schuster GU, Woodhouse LR, Flynn PM, Gordon CM, Pan CG, Rutledge B, Harris DR, Price G, Baker A, Meyer WA 3rd, Wilson CM, Hazra R, Kapogiannis BG, Mulligan K; Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) 109 Study Team. Vitamin D3 supplementation increases spine bone mineral density in adolescents and young adults with human immunodeficiency deficiency virus infection being treated with tenofovir disoproxil fumarate: A randomized, placebo-controlled trial. Clin Infect Dis. 2018 Jan 6;66(2):220-228. doi: 10.1093/cid/cix753. PMID: 29020329; PMCID: PMC5848310
Published: 01/06/2018
-
Vitamin D supplementation does not affect metabolic changes seen with ART initiation
Citation: Muhammed J, Chan ES, Brown TT, Tebas P, McComsey GA, Melbourne K, Hardin R, Willig AL, Yin MT, Ribaudo H, Overton ET. Vitamin D supplementation does not affect metabolic changes seen with ART initiation. Open Forum Infect Dis. 2017 Dec 11;4(4):ofx210. doi: 10.1093/ofid/ofx210. eCollection 2017 Fall. PMID: 29255724. PMCID: PMC5726464
Published: 12/11/2017
-
Risk factors for early mortality on antiretroviral therapy in advanced HIV-infected adults
Citation: Bisson GP, Ramchandani R, Miyahara S, Mngqibisa R, Matoga M, Ngongondo M, Samaneka W, Koech L, Naidoo K, Rassool M, Kirui F, Banda P, Mave V, Kadam D, Leger P, Henestroza G, Manabe YC, Bao J, Kumwenda J, Gupta A, Hosseinipour MC; Adult AIDS Clinical Trials Group A5274 (REMEMBER) Study Team. Risk factors for early mortality on antiretroviral therapy in advanced HIV-infected adults. AIDS. 2017 Oct 23;31(16):2217-2225. doi: 10.1097/QAD.0000000000001606. PMID: 28742529; PMCID: PMC5633516
Published: 10/23/2017
-
Prospective analysis of lipid composition changes with antiretroviral therapy and immune activation in persons living with HIV
Citation: Belury MA, Bowman E, Gabriel J, Snyder B, Kulkarni M, Palettas M, Mo X, Lake JE, Zidar D, Sieg SF, Rodriguez B, Playford MP, Andrade A, Kuritzkes DR, Mehta NN, Lederman MM, Funderburg NT. Prospective analysis of lipid composition changes with antiretroviral therapy and immune activation in persons living with HIV. Pathog Immun. 2017;2(3):376-403. doi: 10.20411/pai.v2i3.218. Epub 2017 Oct 6. PMID: 29098203; PMCID: PMC5663243
Published: 10/06/2017
-
Safety and tolerability of maraviroc-containing regimens to prevent HIV infection in women: A phase 2 randomized trial
Citation: Gulick RM, Wilkin TJ, Chen YQ, Landovitz RJ, Amico KR, Young AM, Richardson P, Marzinke MA, Hendrix CW, Eshleman SH, McGowan I, Cottle LM, Andrade A, Marcus C, Klingman KL, Chege W, Rinehart AR, Rooney JF, Andrew P, Salata RA, Siegel M, Manabe YC, Frank I, Ho K, Santana J, Stekler JD, Swaminathan S, McCauley M, Hodder S, Mayer KH. Safety and tolerability of maraviroc-containing regimens to prevent HIV infection in women: A phase 2 randomized trial. Ann Intern Med 2017 Sep 19;167(6):384-393. PMC5667908
Published: 09/17/2017
-
Antiretroviral initiation is associated with increased skeletal muscle area and fat content
Citation: Erlandson KM, Fiorillo S, Masawi F, Scherzinger A, McComsey GA, Lake JE, Currier J, Stein J, Brown TT. Antiretroviral initiation is associated with increased skeletal muscle area and fat content. AIDS. 2017 Aug 24;31(13):1831-1838. PMID: 28590329. PMCID: PMC5533189.
Published: 08/24/2017
-
Cytomegalovirus urinary shedding in HIV-infected pregnant women and congenital cytomegalovirus infection
Citation: Adachi K, Xu J, Ank B, Watts DH, Mofenson LM, Pilotto JH, Joao E, Santos B, Fonseca R, Kreitchmann R, Pinto J, Mussi-Pinhata MM, Gray G, Theron G, Morgado MG, Bryson YJ, Veloso VG, Klausner JD, Moye J, Nielsen-Saines K; NICHD HPTN 040 Study Team. Cytomegalovirus urinary shedding in HIV-infected pregnant women and congenital cytomegalovirus infection. Clin Infect Dis. 2017 Aug 1;65(3):405-413. doi: 10.1093/cid/cix222. PMID: 28369278; PMCID: PMC5850431
Published: 08/01/2017
-
Why a universal antiretroviral regimen?
Citation: Flexner CW, Clayden P, Venter WDF. Why a universal antiretroviral regimen? Curr Opin HIV AIDS. 2017 Jul;12(4):315-317. doi: 10.1097/COH.0000000000000390. PMID: 28486340. PMCID: PMC5722220.
Published: 07/15/2017
-
Treatment with integrase inhibitor suggests a new interpretation of HIV RNA decay curves that reveals a subset of cells with slow integration
Citation: Cardozo EF, Andrade A, Mellors JW, Kuritzkes DR, Perelson AS, Ribeiro RM. Treatment with integrase inhibitor suggests a new interpretation of HIV RNA decay curves that reveals a subset of cells with slow integration. PLoS Pathog. 2017 Jul 5;13(7):e1006478. doi: 10.1371/journal.ppat.1006478. eCollection 2017 Jul. PMID: 28678879; PMCID: PMC5513547
Published: 07/05/2017
-
Bone mineral density reductions after tenofovir disoproxil fumarate initiation and changes in phosphaturia: a secondary analysis of ACTG A5224s
Citation: Gupta SK, Yeh E, Kitch DW, Brown TT, Venuto CS, Morse GD, Ha B, Melbourne K, McComsey GA. Bone mineral density reductions after tenofovir disoproxil fumarate initiation and changes in phosphaturia: a secondary analysis of ACTG A5224s. J Antimicrob Chemother. 2017 Jul 1;72(7):2042-2048. doi: 10.1093/jac/dkx076. PMID: 28369419. PMCID: PMC5890741.
Published: 07/01/2017
-
Maternal syphilis: an independent risk factor for mother to infant human immunodeficiency virus transmission
Citation: Kinikar A, Gupte N, Bhat J, Bharadwaj R, Kulkarni V, Bhosale R, McIntire KN, Mave V, Suryavanshi N, Patil S, Bollinger R, Gupta A. Maternal syphilis: an independent risk factor for mother to infant human immunodeficiency virus transmission. Sex Transm Dis. 2017 Jun;44(6):371-375. doi: 10.1097/OLQ.0000000000000622. PMID: 28499289 PMCID: PMC5434955
Published: 06/15/2017
-
Decline in CD4 T lymphocytes with monotherapy bridging strategy for non-adherent adolescents living with HIV infection: Results of the IMPAACT P1094 randomized trial
Citation: Agwu AL, Warshaw MG, McFarland EJ, Siberry GK, Melvin AJ, Wiznia AA, Fairlie L, Boyd S, Harding P, Spiegel HML, Abrams EJ, Carey VJ; P1094 Study Team. Decline in CD4 T lymphocytes with monotherapy bridging strategy for non-adherent adolescents living with HIV infection: Results of the IMPAACT P1094 randomized trial. PLoS One. 2017 Jun 12;12(6):e0178075. doi: 10.1371/journal.pone.0178075. eCollection 2017. PMID: 28604824; PMCID: PMC5467803
Published: 06/12/2017
-
HIV-1 DNA decay dynamics with early, long-term virologic control of perinatal infection
Citation: Uprety P, Patel K, Karalius B, Ziemniak C, Hui YC, Brummel SS, Siminski S, Van Dyke RB, Seage III GR, Persaud D. HIV-1 DNA decay dynamics with early, long-term virologic control of perinatal infection. Clin Infect Dis. 2017 Jun 1;64(11):1471-1478. PMID 28329153; PMCID: PMC5407055
Published: 06/01/2017
-
Insulin-like growth factor is associated with changes in body composition with ART initiation
Citation: Erlandson KM, Fiorillo SP, Wagner Cardosa S, Riviere C, Sanchez J, Hakim J, Kumarasamy N,Badal-Faesen S, Lalloo U, Kumwenda J, Campbell TB, Brown TT. IInsulin-like growth factor is associated with changes in body composition with ART initiation. AIDS Res Hum Retroviruses. 2017 Sep;33(9):929-934. doi: 10.1089/AID.2016.0327. Epub 2017 May 16. PMID: 28403619. PMCID: PMC5576217.
Published: 05/16/2017
-
Association of risk of viremia, immunosuppression, serious clinical events, and mortality with increasing age in perinatally human immunodeficiency virus-infected youth
Citation: Neilan AM, Karalius B, Patel K, Van Dyke RB, Abzug MJ, Agwu AL, Williams PL, Purswani M, Kacanek D, Oleske JM, Burchett SK, Wiznia A, Chernoff M, Seage GR 3rd, Ciaranello AL; Pediatric HIV/AIDS Cohort Study and the International Maternal Adolescent and Pediatric AIDS Clinical Trials Network. Association of risk of viremia, immunosuppression, serious clinical events, and mortality with increasing age in perinatally human immunodeficiency virus-infected youth. JAMA Pediatr. 2017 May 1;171(5):450-460. doi:10.1001/jamapediatrics.2017.0141. PMID: 28346597; PMCID: PMC5411314
Published: 05/01/2017
-
Inflammation and immune activation in antiretroviral-treated HIV-1-infected African infants and rotavirus vaccine responses
Citation: Uprety P, Lindsey JC, Levin MJ, Rainwater-Lovett K, Ziemniak C, Bwakura-Dangarembizix M, Kaplan DD, Nelson M, Zadzilla A, Weinberg A, Persaud D. Inflammation and immune activation in antiretroviral-treated HIV-1-infected African infants and rotavirus vaccine responses. J Infect Dis. 2017 Mar 15;215(6):928-932. PMID: 28168269; PMCID: PMC5407055
Published: 03/15/2017
-
Changes in abdominal fat following antiretroviral therapy initiation in HIV-infected individuals correlate with waist circumference and self-reported changes
Citation: Bhagwat P, Ofotokun I, McComsey GA, Brown TT, Moser C, Sugar CA, Currier JS. Changes in abdominal fat following antiretroviral therapy initiation in HIV-infected individuals correlate with waist circumference and self-reported changes. Antivir Ther. 2017;22(7):577-586. doi: 10.3851/IMP3148. Epub 2017 Mar 1. PMID: 28248190. PMCID: PMC5610106.
Published: 03/01/2017
-
Paucity of intact non-induced provirus with early, long-term antiretroviral therapy of perinatal HIV infection
Citation: Rainwater-Lovett K, Ziemniak C, Watson D, Luzuriaga K, Siberry G, Petru A, Chen Y, Uprety P, McManus M, Ho YC, Lamers SL, Persaud D. Paucity of intact non-induced provirus with early, long-term antiretroviral therapy of perinatal HIV infection. PLoS One. 2017 Feb 8;12(2):e0170548. PMID: 28178277; PMCID: PMC5298215
Published: 02/08/2017
-
High prevalence of cryptococcal antigenaemia amongst asymptomatic advanced HIV patients in Pune, India
Citation: Kadam D, Chandanwale A, Bharadwaj R, Nevrekar N, Joshi S, Patil S, Gupte N, Sangle S, Chopade K, Kulkarni V, Balasubramanian U, Suryavanshi N, Jain D, Kanade S, Dharmashale S, Kagal A, Gupta A, Mave V. High prevalence of cryptococcal antigenaemia amongst asymptomatic advanced HIV patients in Pune, India. Indian J Med Microbiol. 2017 Jan-Mar;35(1):105-108. doi: 10.4103/ijmm.IJMM_15_596. PMID: 28303828.
Published: 02/01/2017
-
Enhanced use of phylogenetic data to inform public health approaches to HIV among men who have sex with men
Citation: German D, Grabowski MK, Beyrer C. Enhanced use of phylogenetic data to inform public health approaches to HIV among men who have sex with men. Sex Health. 2017 Feb;14(1):89-96. doi: 10.1071/SH16056. [Epub ahead of print]. PMID: 27584826; PMCID: PMC5408296
Published: 02/01/2017
-
The interaction between equipoise and logistics in clinical trials: A case study
Citation: Warshaw MG, Carey VJ, McFarland EJ, Dawson L, Abrams E, Melvin A, Fairlie L, Spiegel H, Jay J, Agwu AL; IMPAACT P1094 Team. The interaction between equipoise and logistics in clinical trials: A case study. Clin Trials. 2017 Jun;14(3):314-318. doi: 10.1177/1740774517690734. Epub 2017 Jan 31. PMID: 28135804; PMCID: PMC5446272
Published: 01/31/2017
-
Phase 2 study of the safety and tolerability of maraviroc-containing regimens to prevent HIV infection in men who have sex with men (MSM) (HPTN 069/ACTG A5305)
Citation: Gulick RM, Wilkin TJ, Chen YQ, Landovitz RJ, Amico KR, Young AM, Richardson P, Marzinke MA, Hendrix CW, Eshleman SH, McGowan I, Cottle LM, Andrade A, Marcus C, Klingman KL, Chege W, Rinehart AR, Rooney JF, Andrew P, Salata RA, Magnus M, Farley JE, Liu A, Frank I, Ho K, Santana J, Stekler JD, McCauley M, Mayer KH. Phase 2 study of the safety and tolerability of maraviroc-containing regimens to prevent HIV infection in men who have sex with men (MSM) (HPTN 069/ACTG A5305). J Infect Dis. 2017 Jan 15;215(2):238-246. doi: 10.1093/infdis/jiw525. PMID: 27811319. PMCID: PMC5790146.
Published: 01/15/2017
-
Oxidized lipoproteins are associated with markers of inflammation and immune activation in HIV-1 infection
Citation: Kelesidis T, Tran TTT, Brown TT, Moser C, Ribaudo HJ, Dubé MP, Murphy RL, Yang O, McComsey GA, Stein JH, Currier JS. Oxidized lipoproteins are associated with markers of inflammation and immune activation in HIV-1 infection. AIDS. 2016 Nov 13;30(17):2625-2633. PMID: 27603288. PMCID: PMC5083154.
Published: 11/13/2016
-
Benefits and risks of antiretroviral therapy for perinatal HIV prevention
Citation: Fowler MG, Qin M, Fiscus SA, Currier JS, Flynn PM, Chipato T, McIntyre J, Gnanashanmugam D, Siberry GK, Coletti AS, Taha TE, Klingman KL, Martinson FE, Owor M, Violari A, Moodley D, Theron GB, Bhosale R, Bobat R, Chi BH, Strehlau R, Mlay P, Loftis AJ, Browning R, Fenton T, Purdue L, Basar M, Shapiro DE, Mofenson LM; IMPAACT 1077BF/1077FF PROMISE Study Team. Benefits and risks of antiretroviral therapy for perinatal HIV prevention. N Engl J Med. 2016 Nov 3;375(18):1726-1737. PMID: 27806243; PMCID: PMC5214343
Published: 11/03/2016
-
Treatment of HIV infection with a raltegravir-based regimen increases LDL levels, but improves HDL cholesterol efflux capacity
Citation: Funderburg NT, Xu D, Playford MP, Joshi AA, Andrade A, Kuritzkes DR, Lederman MM, Mehta NN. Treatment of HIV infection with a raltegravir-based regimen increases LDL levels, but improves HDL cholesterol efflux capacity. Antivir Ther. 2017;22(1):71-75. doi: 10.3851/IMP3091. Epub 2016 Oct 14. PMID: 27740536; PMCID: PMC5516727
Published: 10/14/2016
-
Neurocognition with maraviroc compared with tenofovir in HIV
Citation: Robertson KR, Miyahara S, Lee A, Brown TT, Chan ES, Berzins B, Rusin D, Eron JJ, Taiwo BO, AIDS Clinical Trials Group (ACTG) 5303 Team. Neurocognition with maraviroc compared with tenofovir in HIV. AIDS. 2016 Sep 24;30(15):2315-21. PMID: 27333088. PMCID: PMC5014739.
Published: 09/24/2016
-
Changes in plasma levels of oxidized lipoproteins and lipoprotein subfractions with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy and associations with common carotid artery intima-media
Citation: Kelesidis T, Tran TTT, Brown TT, Moser C, Ribaudo HJ, Dubé MP, Murphy RL, Yang O, McComsey GA, Stein JH, Currier JS. Changes in plasma levels of oxidized lipoproteins and lipoprotein subfractions with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy and associations with common carotid artery intima-media thickness: ACTG 5260s. Antivir Ther. 2017;22(2):113-126. doi: 10.3851/IMP3093. Epub 2016 Sep 23. PMID: 27661466. PMCID: PMC5364070.
Published: 09/23/2016
-
Changes in markers of T-cell senescence and exhaustion with atazanavir-, raltegravir-, and darunavir-based initial antiviral therapy: ACTG 5260s
Citation: Kelesidis T, Tran TTT, Stein JH, Brown TT, Moser C, Ribaudo HJ, Dubé MP, Murphy RL, Yang O, Currier JS, McComsey GA. Changes in markers of T-cell senescence and exhaustion with atazanavir-, raltegravir-, and darunavir-based iinitial antiviral therapy: ACTG 5260s. J Infect Dis. 2016 Sep 1;214(5):748-52. doi: 10.1093/infdis/jiw253. PMID: 27354367. PMCID: PMC4978379.
Published: 09/01/2016
-
Changes in insulin resistance after initiation of raltegravir or protease inhibitors with tenofovir-emtricitabine: AIDS Clinical Trials Group A5260s
Citation: Dirajlal-Fargo, S, Moser C, Brown TT, Currier JS, Kelesidis T, Dube MP, Stein JH, Ribaudo HJ, McComsey GA. Changes in insulin resistance after initiation of raltegravir or protease inhibitors with tenofovir-emtricitabine: AIDS Clinical Trials Group A5260s. Open Forum Infect Dis. 2016 Aug 29;3(3):ofw174. eCollection 2016 Sep. PMID: 27704026. PMCID: PMC5047417.
Published: 08/29/2016
-
Long-term bone mineral density changes in antiretroviral-treated HIV-infected individuals
Citation: Grant PM, Kitch D, McComsey GA, Collier A, Koletar S, Erlandson KM, Yin MT, Bartali B, Ha B, Melbourne K, Brown TT. Long-term bone mineral density changes in antiretroviral-treated HIV-infected individuals. J Infect Dis. 2016 Aug 15;214(4):607-11. doi: 10.1093/infdis/jiw204. Epub 2016 Jun 20. PMID: 27330053. PMCID: PMC4957444.
Published: 08/15/2016
-
Phenotypic coreceptor tropism in perinatally HIV-infected youth failing antiretroviral therapy
Citation: Agwu AL, Yao TJ, Eshleman SH, Patel K, Huang W, Burchett SK, Siberry GK, Van Dyke RB; Pediatric HIVAIDS Cohort Study. Phenotypic coreceptor tropism in perinatally HIV-infected youth failing antiretroviral therapy. Pediatr Infect Dis J. 2016 Jul;35(7):777-81. doi: 10.1097/INF.0000000000001158. PMID: 27078121; PMCID: PMC4988058
Published: 07/01/2016
-
Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342)
Citation: Castillo-Mancilla JR, Aquilante CL, Wempe MF, Smeaton LM, Firnhaber C, LaRosa AM, Kumarasamy N, Andrade A, Baheti G, Fletcher CV, Campbell TB, Haas DW, MaWhinney S, Anderson PL. Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342). J Antimicrob Chemother. 2016 Jun;71(6):1609-18. doi: 10.1093/jac/dkw005. Epub 2016 Feb 17. PMID: 26892777. PMCID: PMC4867099.
Published: 06/15/2016
-
Population pharmacokinetic drug-drug interaction pooled analysis of existing data for rifabutin and HIV PIs
Citation: Hennig S, Svensson EM, Niebecker R, Fourie PB, Weiner MH, Bonora S, Peloquin CA, Gallicano K, Flexner C, Pym A, Vis P, Olliaro PL, McIlleron H, Karlsson M. Population pharmacokinetic drug-drug interaction pooled analysis of existing data for rifabutin and HIV PIs. J Antimicrob Chemother. 2016 May;71(5):1330-40. doi: 10.1093/jac/dkv470. Epub 2016 Jan 31. PMID: 26832753. PMCID: PMC4830412.
Published: 05/15/2016
-
Effects of pegylated interferon/ribavirin on bone turnover markers in HIV/hepatitis C virus-coinfected patients
Citation: Bedimo R, Kang M, Tebas P, Overton ET, Hollabaugh K, McComsey G, Bhattacharya D, Evans C, Brown TT, Taiwo B. Effects of pegylated interferon/ribavirin on bone turnover markers in HIV/hepatitis C virus-coinfected patients. AIDS Res Hum Retroviruses. 2016 Apr;32(4):325-8. doi: 10.1089/AID.2015.0204. Epub 2015 Nov 24. PMID: 26499270. PMCID: PMC4817562.
Published: 04/15/2016
-
Prevalence and risk factors of micronutrient deficiencies pre- and post-antiretroviral therapy (ART) antiretroviral therapy (ART) among a diverse multicountry cohort of HIV-infected adults
Citation: Shivakoti R, Christian P, Yang WT, Gupte N, Mwelase N, Kanyama C, Pillay S, Samaneka W, Santos B, Poongulali S, Tripathy S, Riviere C, Berendes S, Lama JR,Cardoso SW, Sugandhavesa P, Tang AM, Semba RD, Campbell TB, Gupta A; for the NWCS 319 and PEARLS Study Team. Prevalence and risk factors of micronutrient deficiencies pre- and post-antiretroviral therapy (ART) antiretroviral therapy (ART) among a diverse multicountry cohort of HIV-infected adults. Clin Nutr. 2016 Feb;35(1):183-9. doi: 10.1016/j.clnu.2015.02.002. PMID: 25703452. PMCID: PMC4531105.
Published: 02/15/2016
-
Preexposure prophylaxis for HIV infection integrated with municipal- and community-based sexual health services
Citation: Liu AY, Cohen SE, Vittinghoff E, Anderson PL, Doblecki-Lewis S, Bacon O, Chege W, Postle BS, Matheson T, Amico KR, Ziegler T, Rawlings MK, Trainor N, Blue RW, Estrada W, Coleman ME, Cardenas G, Feaster DJ, Grant R, Philip SS, Elion R, Buchbinder S, Kolber MA. Preexposure prophylaxis for HIV infection integrated with municipal- and community-based sexual health services. JAMA Intern Med. 2016 Jan;176(1):75-84. doi: 10.1001/jamainternmed.2015.4683. PMID: 26571482. PMCID: PMC5042323.
Published: 01/15/2016
-
Dose frequency ranging pharmacokinetic study of tenofovir-emtricitabine after directly observed dosing in healthy volunteers to establish adherence benchmarks (HPTN 066)
Citation: Hendrix CW, Andrade A, Bumpus NN, Kashuba AD, Marzinke MA, Moore A, Anderson PL, Bushman LR, Fuchs EJ, Wiggins I, Radebaugh C, Prince HA, Bakshi RP, Wang R, Richardson P, Shieh E, McKinstry L, Li X, Donnell D, Elharrar V, Mayer KH, Patterson KB.Dose frequency ranging pharmacokinetic study of tenofovir-emtricitabine after directly observed dosing in healthy volunteers to establish adherence benchmarks (HPTN 066). AIDS Res Hum Retroviruses. 2016 Jan;32(1):32-43. doi: 10.1089/AID.2015.0182. Epub 2015 Oct 15.
Published: 01/15/2016
-
HIV salvage therapy does not require nucleoside reverse transcriptase inhibitors: A randomized, controlled trial
Citation: Tashima KT, Smeaton LM, Fichtenbaum CJ, Andrade A, Eron JJ, Gandhi RT, Johnson VA, Klingman KL, Ritz J, Hodder S, Santana JL, Wilkin T, Haubrich RH; A5241 Study Team. HIV salvage therapy does not require nucleoside reverse transcriptase inhibitors: A randomized, controlled trial. Ann Intern Med. 2015 Dec 15;163(12):908-17. doi: 10.7326/M15-0949. Epub 2015 Nov 24. PMID: 26595748. PMCID: PMC4681296.
Published: 12/15/2015
-
Changing trends in complications and mortality rates among US youth and young adults with HIV infection in the era of combination antiretroviral therapy
Citation: Mirani G, Williams PL, Chernoff M, Abzug MJ, Levin MJ, Seage GR 3rd, Oleske JM, Purswani MU, Hazra R, Traite S, Zimmer B, Van Dyke RB; IMPAACT P1074 Study Team. Changing trends in complications and mortality rates among US youth and young adults with HIV infection in the era of combination antiretroviral therapy. Clin Infect Dis. 2015 Dec 15;61(12):1850-61. doi: 10.1093/cid/civ687. Epub 2015 Aug 12. PMID: 26270680; PMCID: PMC4657532
Published: 12/15/2015
-
Early HIV RNA decay during raltegravir-containing regimens exhibits two distinct subphases (1a and 1b)
Citation: Andrade A, Guedj J, Rosenkranz SL, Lu D, Mellors J, Kuritzkes DR, Perelson AS, Ribeiro RM; ACTG A5249s protocol team. Early HIV RNA decay during raltegravir-containing regimens exhibits two distinct subphases (1a and 1b). AIDS. 2015 Nov 28;29(18):2419-26. doi: 10.1097/QAD.0000000000000843. PMID: 26558541. PMCID: PMC4646723.
Published: 11/28/2015
-
A tailored approach to launch community coalitions focused on achieving structural changes: Lessons learned from a HIV prevention mobilization study
Citation: Chutuape KS, Willard N, Walker BC, Boyer CB, Ellen J; Adolescent Medicine Trials Network for HIVAIDS Interventions. A tailored approach to launch community coalitions focused on achieving structural changes: Lessons learned from a HIV prevention mobilization study. J Public Health Manag Pract. 2015 Nov-Dec;21(6):546-55. doi: 10.1097/PHH.0000000000000182. PMID: 26785397; PMCID: PMC4721266
Published: 11/01/2015
-
CD4+ and viral load outcomes of antiretroviral therapy switch strategies after virologic failure of combination antiretroviral therapy in perinatally HIV-infected youth in the United States
Citation: Fairlie L, Karalius B, Patel K, van Dyke RB, Hazra R, Hernán MA, Siberry GK, Seage GR 3rd, Agwu A, Wiznia A; Pediatric HIV AIDS Cohort Study (PHACS), The International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT). CD4+ and viral load outcomes of antiretroviral therapy switch strategies after virologic failure of combination antiretroviral therapy in perinatally HIV-infected youth in the United States. AIDS. 2015 Oct 23;29(16):2109-19. doi: 10.1097/QAD.0000000000000809. PMID: 26182197; PMCID: PMC4612147
Published: 10/23/2015
-
Efavirenz pharmacokinetics and pharmacodynamics in HIV-infected persons receiving rifapentine and isoniazid for tuberculosis prevention
Citation: Podany AT, Bao Y, Swindells S, Chaisson RE, Andersen JW, Mwelase T, Supparatpinyo K, Mohapi L, Gupta A, Benson Cam, Kim P, Fletcher CV on behalf of the ACTG A5279 Study Team. Efavirenz pharmacokinetics and pharmacodynamics in HIV-infected persons receiving rifapentine and efavirenz-pharmacokinetics-and-pharmacodynamics-in-hiv-infected-person. Clin Infect Dis. 2015 Oct 15;61(8):1322-7. doi: 10.1093/cid/civ464. Epub 2015 Jun 16. PMID: 26082504. PMCID: PMC4583578.
Published: 10/15/2015
-
Changes in bone mineral density after antiretroviral initiation with tenofovir disoproxil fumarate-emtricitabine plus atazanavir-ritonavir, darunavir-ritonavir, or raltegravir
Citation: Brown TT, Moser C, Currier JS, Ribaudo HJ, Rothenberg J, Kelesidis T, Yang O, Dubé MP, Murphy RL, Stein JH, McComsey GA. Changes in bone mineral density after antiretroviral initiation with tenofovir disoproxil fumarate-emtricitabine plus atazanavir-ritonavir, darunavir-ritonavir, or raltegravir. J Infect Dis. 2015 Oct 15;212(8):1241-9. doi: 10.1093/infdis/jiv194. Epub 2015 May 5. PMID: 25948863. PMCID: PMC4577040.
Published: 10/15/2015
-
Antiretroviral treatment initiation does not differentially alter neurocognitive functioning over time in youth with behaviorally acquired HIV
Citation: Nichols SL, Bethel J, Kapogiannis BG, Li T, Woods SP, Patton ED, Ren W, Thornton SE, Major-Wilson HO, Puga AM, Sleasman JW, Rudy BJ, Wilson CM, Garvie PA; Adolescent Medicine Trials Network for HIV/AIDS Interventions. Antiretroviral treatment initiation does not differentially alter neurocognitive functioning over time in youth with behaviorally acquired HIV. J Neurovirol. 2016 Apr;22(2):218-30. doi: 10.1007/s13365-015-0389-0. Epub 2015 Oct 13. PMID: 26463526; PMCID: PMC4781894
Published: 10/13/2015